Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409318 | 0.87 | MEN1 (0.41) | POLBMAPTHDAC1HDAC8LMNA | |
| SCHEMBL2960082 | 0.84 | P2RX3 (0.44) | POLBTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL2951145 | 0.83 | GLA (0.48) | AGTR1AGTR2TP53LMNA | |
| SCHEMBL2337768 | 0.83 | TLR8 (0.37) | TLR8POLBTP53MAPTLMNA | |
| SCHEMBL30361134 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL661457 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL662975 | 0.81 | LMNA (0.48) | AGTR1AGTR2MAPTSMN1; SMN2LMNA | |
| SCHEMBL661098 | 0.77 | ALDH1A1 (0.36) | TLR8POLBTP53LMNATSHR | |
| SCHEMBL663298 | 0.77 | TLR7 (0.39) | TLR8AGTR1AGTR2TLR7HDAC1 | |
| SCHEMBL30361146 | 0.77 | ALDH1A1 (0.36) | TLR8POLBTP53LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | TLR8 2413/4885POLB 3175/4885EDNRA 3081/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | TLR8 2413/4885POLB 3175/4885EDNRA 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.